Phase 3 Study of Oral Therapy for ‘Off’ Episodes in Parkinson’s Now Enrolling Patients

Cynapsus Therapeutics recently provided an update on APL-130277, its sublingual formulation of apomorphine hydrochloride or apomorphine. Apomorphine injection is the only treatment approved for acute, intermittent “off” episodes in advanced Parkinson’s disease (PD) patients. Motor symptoms such as tremor at rest, rigidity, and impaired movement or freezing, as well as difficulties with starting…

Cynapsus and MonoSol Enter Licensing Agreement for Sublingual Film Treatment of Parkinson ‘Off’ Episodes

Cynapsus Therapeutics and MonoSol Rx announced that they have signed a global licensing agreement for select intellectual property, including existing and future patents and patent applications, covering all oral films containing apomorphine for the treatment of “off” episodes  in patients with Parkinson’s disease (PD). According to the Michael J. Fox Foundation for…